OncLive July 1, 2020
Maurie Markman, MD

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.

Perhaps no debate is more intense in all of clinical investigative medicine than the one on the relevance of focusing studies on population based versus molecular-based strategies. Certain academic commentators have even used the coronavirus disease 2019 (COVID-19) pandemic to highlight their arguments that the National Institutes of Health and other funding agencies should spend less on understanding disease entities at the molecular level and far more on illnesses affecting large populations. This never-ending argument misses the most critical point, which is the basic observation that these 2 approaches to human disease are complementary rather than in conflict or opposition.

To be clear,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma / Biotech, Population Health Mgmt, Precision Medicine, Provider
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine
Shifting the Paradigm in Whole-Genome Sequencing for Newborns
Cracking the code of DNA circles in cancer: Scientists uncover potential therapy

Share This Article